Beigene logo

BGNE - Beigene News Story

$310.37 5.0  1.6%

Last Trade - 4:14pm

Sector
Healthcare
Size
Large Cap
Market Cap £20.23bn
Enterprise Value £17.26bn
Revenue £222.2m
Position in Universe 452nd / 6849

BRIEF-Beigene Got Approval From NMPA To Begin Manufacturing Commercial Supply Of Tislelizumab

Thu 8th April, 2021 1:59am
April 8 (Reuters) - Beigene Ltd  6160.HK :
    * GOT APPROVAL FROM NMPA TO BEGIN MANUFACTURING COMMERCIAL
SUPPLY
OF ITS APPROVED ANTI-PD-1 ANTIBODY, TISLELIZUMAB
    * ADDITIONAL CONSTRUCTION IN GUANGZHOU IN PROGRESS TO BRING
TOTAL
CAPACITY TO 64,000 LITERS SEEN COMPLETED BY END 2022

Source text for Eikon:  urn:newsml:reuters.com:*:nHKS4Gd1yd
Further company coverage:  6160.HK 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.